NEUREN PHARMACEUTICALS LIMITEDNEUREN PHARMACEUTICALS LIMITEDNEUREN PHARMACEUTICALS LIMITED

NEUREN PHARMACEUTICALS LIMITED

No trades
See on Supercharts
Market capitalization
‪2.54 B‬AUD
‪157.08 M‬AUD
‪231.93 M‬AUD
‪110.12 M‬
Beta (1Y)
1.51

About NEUREN PHARMACEUTICALS LIMITED

CEO
Jonathan Charles Pilcher
Headquarters
Camberwell
Founded
2004
ISIN
NZNEUE0001S8
FIGI
BBG000CS0GB6
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of NEU is 18.92 AUD — it has decreased by 3.81% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange NEUREN PHARMACEUTICALS LIMITED stocks are traded under the ticker NEU.
NEUREN PHARMACEUTICALS LIMITED is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
NEU stock is 5.64% volatile and has beta coefficient of 1.51. Check out the list of the most volatile stocks — is NEUREN PHARMACEUTICALS LIMITED there?
One year price forecast for NEUREN PHARMACEUTICALS LIMITED has a max estimate of 31.00 AUD and a min estimate of 22.80 AUD.
NEU earnings for the last quarter are 0.37 AUD per share, whereas the estimation was 0.32 AUD resulting in a 14.95% surprise. The estimated earnings for the next quarter are 0.98 AUD per share. See more details about NEUREN PHARMACEUTICALS LIMITED earnings.
NEUREN PHARMACEUTICALS LIMITED revenue for the last quarter amounts to ‪64.41 M‬ AUD despite the estimated figure of ‪62.50 M‬ AUD. In the next quarter revenue is expected to reach ‪165.29 M‬ AUD.
Yes, you can track NEUREN PHARMACEUTICALS LIMITED financials in yearly and quarterly reports right on TradingView.
NEU stock has fallen by 8.16% compared to the previous week, the month change is a 8.38% fall, over the last year NEUREN PHARMACEUTICALS LIMITED has showed a 34.18% increase.
NEU net income for the last quarter is ‪109.28 M‬ AUD, while the quarter before that showed ‪47.81 M‬ AUD of net income which accounts for 128.59% change. Track more NEUREN PHARMACEUTICALS LIMITED financial stats to get the full picture.
Today NEUREN PHARMACEUTICALS LIMITED has the market capitalization of ‪2.51 B‬, it has decreased by 3.15% over the last week.
No, NEU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NEU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEUREN PHARMACEUTICALS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
NEU reached its all-time high on Dec 28, 2023 with the price of 25.95 AUD, and its all-time low was 0.05 AUD and was reached on Mar 5, 2009.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEUREN PHARMACEUTICALS LIMITED technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEUREN PHARMACEUTICALS LIMITED stock shows the buy signal. See more of NEUREN PHARMACEUTICALS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NEUREN PHARMACEUTICALS LIMITED future price: according to them, NEU price has a max estimate of 31.00 AUD and a min estimate of 22.80 AUD. Read a more detailed NEUREN PHARMACEUTICALS LIMITED forecast: see what analysts think of NEUREN PHARMACEUTICALS LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEUREN PHARMACEUTICALS LIMITED EBITDA is ‪199.25 M‬ AUD, and current EBITDA margin is 85.91%. See more stats in NEUREN PHARMACEUTICALS LIMITED financial statements.